A STEP FORWARD.
Context Therapeutics is dedicated to creating new medicines to treat hormone-responsive (HR+) cancers. We are building Context Therapeutics to become a global company that will discover, develop and market groundbreaking cancer treatments to patients around the world, eliminating the fear that comes with a cancer diagnosis. Context’s lead program is Apristor® , an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast cancer.
Why HR+ Cancer?
Breast, prostate, and gastrointestinal cancers are poorly addressed and result in >100,000 deaths per year in the United States.
The rapid advances in the field of immune-oncology ("IO") have not trickled down to HR+ cancers.
The underlying drivers of HR+ cancer growth (hormones and their associated regulatory proteins) are well understood relative to other cancers.
The Unmet Need